Skip to main content

Author: Customer Service

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma (“DLBCL”) in China. The first patient received the first dose on March 20, 2026. DLBCL is the most common form of aggressive non-Hodgkin lymphoma (“NHL”) worldwide, accounting for approximately 40% of all NHL cases in China.1  In 2022, approximately 81,000 new cases of NHL are estimated to have been diagnosed in China.2 Bruton’s tyrosine kinase (“BTK”) is considered a validated target for drugs that aim to treat certain hematological cancers. HMPL-760 is a highly...

Continue reading

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast DetailsApogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events....

Continue reading

Perseus Makes 9.9% Investment in Aurum Resources

Perth, March 23, 2026 (GLOBE NEWSWIRE) — PERSEUS MAKES 9.9% INVESTMENT IN AURUM RESOURCES Perth, Western Australia/March 23, 2026/Perseus Mining Limited (ASX/TSX: PRU) (Perseus or the Company) is pleased to announce that it has acquired a relevant interest in 9.9% of the issued shares of Aurum Resources Limited (Aurum) (ASX: UAE) via participation in the Aurum equity raising announced today (Aurum Share Acquisition). Aurum is an emerging mineral development company listed on the ASX. Aurum’s key asset is the Boundiali Gold Project, a pre-development and pre-study gold project located in the North of Côte d’Ivoire, West Africa. The Boundiali Gold Project has a reported Ore Resource of 100Mt @ 1.0g/t Au for 3.0Moz of gold1. The Boundiali Gold Project is located to the south and along strike of Perseus’s Sissingué gold mine, which...

Continue reading

Nissay Asset Management Adopts Triton

NEW YORK, March 22, 2026 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NYSE: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, announces today that Nissay Asset Management Corporation (Head office: Chiyoda-ku, Tokyo; hereinafter “Nissay Asset Management”) selected Triton to streamline its trading operations across global markets. Nissay Asset Management is a 100% subsidiary asset management company established in 1995 that brings together the Group’s asset management capabilities. The company leverages its expertise in insurance asset management to supply a wide range of investment products that meet the needs of pension funds, as well as individual investors and other customers, for long-term, stable...

Continue reading

Walrus Pump expanding into the European Market

Demonstrates Its Ambition to Grow Internationally at MCE 2026MCE – Mostra Convegno ExpocomfortWalrus Pump expanding into the European MarketMILAN, March 22, 2026 (GLOBE NEWSWIRE) — In response to the rapid global development of energy efficiency and intelligent building technologies, Taiwan’s professional pump brand, Walrus Pump, will participate in MCE – Mostra Convegno Expocomfort from 24 to 27 March 2026. Held in Milan, MCE is widely regarded as one of the most influential international exhibitions in Europe for the HVAC and water systems industries, serving as a key global platform for technological exchange in heating, ventilation and water management. Through its participation, Walrus Pump demonstrates its determination to expand into the European market, with its core positioning as a provider of high-quality water...

Continue reading

Vemanti Group Issues Statement Regarding ONUS Platform Status

Irvine, CA, March 21, 2026 (GLOBE NEWSWIRE) — Vemanti Group, Inc. (“Vemanti” or the “Company”) (OTC: VMNT) announced today that it is aware that the ONUS Pro platform (the “Platform”) has experienced a significant service disruption affecting users’ ability to access their accounts and funds. The Company has received complaints from Platform users who are unable to access their accounts and funds. The Company takes these complaints very seriously and is treating this matter with the highest priority. As a parent holding company without direct access to the Platform’s systems, the Company is unable to intervene directly on behalf of affected users, but its executive team is working urgently to establish contact with the appropriate personnel at the Platform and will provide further...

Continue reading

HII Celebrates 2025 Graduates of The Newport News Shipbuilding Apprentice School

NEWPORT NEWS, Va., March 21, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) hosted commencement exercises today, celebrating 128 graduates of the company’s Newport News Shipbuilding Apprentice School. The ceremony was held at Liberty Live Church in Hampton. Linda McMahon, U.S. secretary of education, delivered the keynote commencement address. “On the eve of America’s 250th anniversary, I am reminded of how much we have relied on skilled workers to build and sustain our nation,” McMahon told graduates. “Today, you join that proud tradition. This path you have chosen is one of purpose, opportunity, and lasting impact, and it will help carry our country forward for generations to come.” HII hosted McMahon at NNS Friday for a tour of the shipyard and The Apprentice School. McMahon also participated in a roundtable discussion with shipbuilders...

Continue reading

Kaldalón hf.: Final Agenda, Proposals and Candidacies for the AGM to be held on 26 March 2026

The Annual General Meeting of Kaldalón hf. will be held on Thursday, 26 March 2026, at 16:00 at Reykjavík Natura, Nauthólsvegur 52, 101 Reykjavík. The deadline for submitting candidacies for the Board of Directors and the Nomination Committee of Kaldalón hf. has expired. The following candidates have submitted their candidacies for election to the Board of Directors of the Company:Álfheiður Ágústsdóttir Ásgeir Helgi Reykfjörð Gylfason Haukur Guðmundsson Haukur Hafsteinsson Pálína María GunnlaugsdóttirThe following candidates have submitted their candidacies for election as alternate directors:Gunnar Henrik B. Gunnarsson Harpa GuðnadóttirThe Board of Directors has assessed the candidacies as valid pursuant to Article 63 a of the Icelandic Act on Public Limited Companies. As no other candidacies for the Board of Directors or alternate...

Continue reading

IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy

The first wireless ionization chamber array for particle therapy PSQA delivers fast, reliable verification for proton and carbon ion treatments, supporting emerging techniques such as FLASH and ARC radiotherapy. Louvain-la-Neuve, Belgium, 21 March 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global provider of dosimetry and quality assurance (QA) solutions, announces the launch of myQA MatriXX AiR, a high resolution, wireless 2D ionization chamber array designed for patient specific quality assurance (PSQA) in particle therapy, including proton and carbon ion treatments. This new solution further demonstrates IBA’s role as a driving force in innovation and reinforces its leadership in quality assurance for particle‑beam therapies. In radiation therapy, quality assurance is...

Continue reading

Financière de Tubize – Annual report 2025

Annual Report 2025Regulated information 21 March 2026 The board of directors of Financière de Tubize has established the 2025 annual report. This report is available on the website www.financiere-tubize.beProfit for the financial year: € 93.2 million (€ 90.1 million in 2024, + 3.5%), Full repayment of bank debt in May 2025 (€ 41.3 million at 31 December 2024), Acquisition, in 2025, of 24,487 UCB shares, at an average price of €178.27, for a total amount of €4.4 million, increasing the holding of the Company in UCB from 36.27% on 31 December 2024 to 36.28% on 31 December 2025.If the general shareholders meeting of 24 April 2026 approves the 2025 annual accounts, including the proposed result appropriation, a gross dividend of € 1.08 (compared to €1.04 for financial year 2024, an increase of 3.85%) will be payable as from 11 May 2026...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.